197 related articles for article (PubMed ID: 11032356)
21. Variations in erythropoiesis and serum ferritin during erythropoietin therapy for anaemia of end-stage renal disease.
Barosi G; Merlo C; Palestra P; Liberato NL; Guarnone R; Di Dio F; Piazza V; Salvadeo A
Acta Haematol; 1993; 90(1):13-8. PubMed ID: 8237268
[TBL] [Abstract][Full Text] [Related]
22. Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study.
Hedenus M; Birgegård G; Näsman P; Ahlberg L; Karlsson T; Lauri B; Lundin J; Lärfars G; Osterborg A
Leukemia; 2007 Apr; 21(4):627-32. PubMed ID: 17252006
[TBL] [Abstract][Full Text] [Related]
23. Iron-replete hemodialysis patients do not require higher EPO dosages when converting from subcutaneous to intravenous administration: results of the Italian Study on Erythropoietin Converting (ISEC).
Pizzarelli F; David S; Sala P; Icardi A; Casani A
Am J Kidney Dis; 2006 Jun; 47(6):1027-35. PubMed ID: 16731298
[TBL] [Abstract][Full Text] [Related]
24. Iron management during recombinant human erythropoietin therapy.
Van Wyck DB
Am J Kidney Dis; 1989 Aug; 14(2 Suppl 1):9-13. PubMed ID: 2757026
[TBL] [Abstract][Full Text] [Related]
25. Australian haemodialysis patients on intravenous epoetin alfa or intravenous darbepoetin alfa: how do they compare?
Pussell BA; Walker R;
Nephrology (Carlton); 2007 Apr; 12(2):126-9. PubMed ID: 17371333
[TBL] [Abstract][Full Text] [Related]
26. Maintaining over time clinical performance targets on anaemia correction in unselected population on chronic dialysis at 20 Italian centres. Data from a retrospective study for a clinical audit.
Soffritti S; Russo G; Cantelli S; Gilli G; Catizone L
BMC Nephrol; 2009 Oct; 10():33. PubMed ID: 19852833
[TBL] [Abstract][Full Text] [Related]
27. Stepwise correction of anaemia by subcutaneous administration of human recombinant erythropoietin in patients with chronic renal failure maintained by continuous ambulatory peritoneal dialysis.
Stevens JM; Auer J; Strong CA; Hughes RT; Oliver DO; Winearls CG; Cotes PM
Nephrol Dial Transplant; 1991; 6(7):487-94. PubMed ID: 1922910
[TBL] [Abstract][Full Text] [Related]
28. Therapeutic equivalence of epoetin zeta and alfa, administered subcutaneously, for maintenance treatment of renal anemia.
Krivoshiev S; Wizemann V; Czekalski S; Schiller A; Pljesa S; Wolf-Pflugmann M; Siebert-Weigel M; Koytchev R; Bronn A;
Adv Ther; 2010 Feb; 27(2):105-17. PubMed ID: 20369312
[TBL] [Abstract][Full Text] [Related]
29. Regular low-dose intravenous iron therapy improves response to erythropoietin in haemodialysis patients.
Taylor JE; Peat N; Porter C; Morgan AG
Nephrol Dial Transplant; 1996 Jun; 11(6):1079-83. PubMed ID: 8671972
[TBL] [Abstract][Full Text] [Related]
30. Is it time for a paradigm shift? Is erythropoietin deficiency still the main cause of renal anaemia?
Eschbach JW; Varma A; Stivelman JC
Nephrol Dial Transplant; 2002; 17 Suppl 5():2-7. PubMed ID: 12091599
[TBL] [Abstract][Full Text] [Related]
31. [Iron deficiency is a common cause of bad response to epoetin treatment. It's important to follow iron status--not only the Hb value].
Wallerstedt SM; Ljungman S; Broms E; Andrén L
Lakartidningen; 2005 Sep 12-18; 102(37):2550-1, 2553-5. PubMed ID: 16200900
[TBL] [Abstract][Full Text] [Related]
32. [Erythropoietin-beta in the treatment of anemia in patients with chronic renal insufficiency].
Dimković N
Med Pregl; 2001; 54(5-6):235-40. PubMed ID: 11759218
[TBL] [Abstract][Full Text] [Related]
33. The efficacy of once weekly compared with two or three times weekly subcutaneous epoetin beta: results from a randomized controlled multicentre trial. Swedish Study Group.
Weiss LG; Clyne N; Divino Fihlho J; Frisenette-Fich C; Kurkus J; Svensson B
Nephrol Dial Transplant; 2000 Dec; 15(12):2014-9. PubMed ID: 11096148
[TBL] [Abstract][Full Text] [Related]
34. Weekly low-dose treatment with intravenous iron sucrose maintains iron status and decreases epoetin requirement in iron-replete haemodialysis patients.
Schiesser D; Binet I; Tsinalis D; Dickenmann M; Keusch G; Schmidli M; Ambühl PM; Lüthi L; Wüthrich RP
Nephrol Dial Transplant; 2006 Oct; 21(10):2841-5. PubMed ID: 16891647
[TBL] [Abstract][Full Text] [Related]
35. Epoetin beta (NeoRecormon) corrects anaemia in patients with hormone-refractory prostate cancer and bone metastases.
Bogdanos J; Karamanolakis D; Milathianakis K; Repousis P; Chloraki-Bobota A; Majed H; Pagalou-Thoua E; Tsintavis A; Koutsilieris M
Anticancer Res; 2004; 24(3b):1957-61. PubMed ID: 15274384
[TBL] [Abstract][Full Text] [Related]
36. Anaemia management in patients with chronic kidney disease: Taiwan practice guidelines.
Hung SC; Kuo KL; Tarng DC; Hsu CC; Wu MS; Huang TP
Nephrology (Carlton); 2014 Dec; 19(12):735-9. PubMed ID: 25156587
[TBL] [Abstract][Full Text] [Related]
37. Haemoglobin response to subcutaneous versus intravenous epoetin alfa administration in iron-replete haemodialysis patients.
Leikis MJ; Kent AB; Becker GJ; McMahon LP
Nephrology (Carlton); 2004 Jun; 9(3):153-60. PubMed ID: 15189176
[TBL] [Abstract][Full Text] [Related]
38. Darbepoetin alfa effectively maintains haemoglobin concentrations at extended dose intervals relative to intravenous or subcutaneous recombinant human erythropoietin in dialysis patients.
Brunkhorst R; Bommer J; Braun J; Haag-Weber M; Gill C; Wagner J; Wagener T;
Nephrol Dial Transplant; 2004 May; 19(5):1224-30. PubMed ID: 14993489
[TBL] [Abstract][Full Text] [Related]
39. [Current issues in erythropoietin therapy of renal anemia].
Zakar G
Lege Artis Med; 2007 Oct; 17(10):667-73. PubMed ID: 19227596
[TBL] [Abstract][Full Text] [Related]
40. Strategies for iron supplementation: oral versus intravenous.
Macdougall IC
Kidney Int Suppl; 1999 Mar; 69():S61-6. PubMed ID: 10084288
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]